ADCs: The Next Phase Of Innovation

By Sophia Shamsi, Senior Market Analyst, Hansonwade Intelligence

The field of antibody-drug conjugates (ADCs) is at a pivotal moment, with developers striving to surpass the limitations of traditional therapeutic windows. This includes enhancing drug-to-antibody ratios (DAR) to achieve greater potency, adopting multispecific approaches to tackle tumor heterogeneity, and expanding payloads beyond conventional cytotoxic. However, innovation alone is insufficient. Higher DARs can increase hydrophobicity, which leads to faster systemic clearance. Multispecific ADCs introduce design complexity, and novel payloads require optimized delivery strategies. Beyond the scientific advancements, success in this field depends on manufacturability, scalability, regulatory acceptance, and commercial viability.

This e-book delves into how advancements in high-DAR ADCs, multispecific designs, and novel payloads are pushing the boundaries of what is possible while also presenting new challenges. The future of ADCs is not solely about innovation but about ensuring these breakthroughs translate into viable, effective products that can be successfully manufactured, scaled, and accepted by regulatory bodies.

Access the full e-book to learn more.